Clinical Trial Update: Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of single-agent decitabine in TP53-mutated relapsed/refractory acute myeloid leukemia was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Relapsed Adult

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia, Relapsed, Adult | Phase 2 | Status: TERMINATED | Results posted: 2022-03-18